Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
STOCKHOLM, Sweden, 2 February 2024 – Impilo has closed its investment in Avia Pharma Holding AB (“Avia” or the “Company”), a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Continuing on Impilo’s long-term ambitions of building a leading Northern European OTC/Rx platform, and the work through Mallax, Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.
Avia was founded in 2016 and focuses on medically positioned products within dermatology, allergy, women’s health, urology and general OTC products. The Company has successfully executed on its strategy to build its own brand portfolio and to grow its Northern European presence over time, through a combination of M&A (having already done 6 since inception), in-licensing of additional products and growing market share across the portfolio. Avia is today a well-diversified platform present across the Nordics and Germany with headquarters in Stockholm, Sweden, and with offices in Germany and Finland.
“Impilo is very excited to partner with Avia management and the co-founders Jacob Calmvik and Jostein Lønberg. We have followed Avia’s growth journey closely and look forward to supporting the Company in its effort to build a leading platform in the OTC/Rx space.”, says Carolina Oscarius Dahl, Partner at Impilo
As a testament to the ambitious growth agenda, in the week after Impilo closed its investment in Avia, the Company closed the acquisition of Neubourg Skin Care GmbH (“Neubourg”), a leading German dermatology company, specialized in skin, foot and nail care. Through the acquisition of Neubourg, Avia adds a strong dermatology brand portfolio in Germany to its platform, including, Allpresan, the German market leader in foam-based foot care.
Jacob Calmvik, Co-Founder and CEO of Avia, comments: “The partnership with Impilo is an important step for Avia and will enable us to fully execute on our strategy. Together with Impilo we will continue to scale the platform at a high pace through organic and inorganic growth initiatives. Further, we are happy to welcome Per Edelmann, who comes with vast industry experience, as the new chairperson of the board.”
For further information, please contact:
Jacob Calmvik, CEO of Avia, jacob.calmvik@aviapharma.se
Carolina Oscarius Dahl, Partner at Impilo, carolina.oscarius.dahl@impilo.se
About Avia Pharma
Avia is a leading Swedish OTC/Rx distribution platform with presence in the Nordics and Germany, focusing on medically positioned products within dermatology, allergy, women’s health, urology and general OTC products with brands such as Nix, Duroferon and Allergika. With the most recent acquisition of Neubourg, Avia has an annual turnover of more than SEK 600m. Learn more about Avia Pharma at www.aviapharma.se/
About Impilo
Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in pharmaceuticals, medical technology, healthcare and care services and other health-related areas. The Company strives to increase the value of its investments through long-term active ownership. Impilo has a well-diversified portfolio of investments and has raised c. SEK 10 billion in capital from leading Nordic and international investors since its inception in 2017. Learn more about Impilo at www.impilo.se/en/